Ankasa Regenerative Therapeutics is developing proprietary formulations of the WNT3A stem cell activator to accelerate tissue healing and promote organ and tissue regrowth. The company is initially targeting a localized WNT3A therapy for spinal fusion surgery and plans to begin a clinical trial in that indication within about 30 months. Ankasa reports multiple proofs of efficacy for WNT3A in various animal models of bone repair and positions its approach as a potential alternative to commercially used BMP-2, which has known complications. The company intends to investigate WNT3A in additional bone and other tissue-repair applications beyond spinal fusion. Management and scientific leadership cited in the article include CEO Sanford J. Madigan, Ph.D., Jill A. Helms, D.D.S., Ph.D., and SAB chair David Lacey, M.D. Ankasa has received initial funding support via a Series A financing to advance its preclinical and planned clinical programs.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2015